N/O-linked Degrons and Degronimers for protein degradation

1. A compound of Formula:

or a pharmaceutically acceptable salt thereof;

wherein:

n is 0, 1, or 2;

R 5 is selected at each instance from the group consisting of hydrogen, alkyl, alkenyl, halogen, hydroxyl, alkoxy, amino, cyano, —NH(aliphatic), —N(aliphatic) 2 , —NHSO 2 (aliphatic), —N(aliphatic)SO 2 alkyl, —NHSO 2 (aryl, heteroaryl or heterocycle), C(O)R 4 , —N(alkyl)SO 2 (aryl, heteroaryl or heterocycle) —NHSO 2 alkenyl, —N(alkyl)SO 2 alkenyl, —NHSO 2 alkynyl, —N(alkyl)SO 2 alkynyl, haloalkyl, aliphatic, aryl, heteroaryl, and carbocyclic;

each of which R 5 can be optionally substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, amino, —NHalkyl, —N(alkyl) 2 , aryl, heterocycle, heteroaryl, haloalkyl, and cycloalkyl;

R 4 is selected at each instance from the group consisting of alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, amino, —NHalkyl, —N(alkyl) 2 , —NHSO 2 alkyl, —N(alkyl)SO 2 alkyl, —NHSO 2 aryl, —N(alkyl)SO 2 aryl, —NHSO 2 alkenyl, —N(alkyl)SO 2 alkenyl, —NHSO 2 alkynyl, —N(alkyl)SO 2 alkynyl, and haloalkyl;

R 12 is Linker-Targeting Ligand;

Linker is:

X 1 and X 2 are independently selected from the group consisting of bond, NH, NR 25 , CH 2 , CHR 25 , C(R 25 ) 2 , O, and S;

R 20 , R 21 , R 22 , R 23 , and R 24 are independently selected from the group consisting of bond, alkyl, —C(O)— —C(O)O—, —OC(O)—, —C(O)alkyl, —C(O)Oalkyl, —C(S)—, —SO 2 —, —S(O)—, —C(S)—, —C(O)NH—, —NHC(O)—, —N(alkyl)C(O)—, —C(O)N(alkyl)-, —O—, —S—, —NH—, —N(alkyl)-, —CH(—O—R 26 )—, —CH(—NHR 25 )—, —CH(—NH 2 )—, —CH(—NR 25 2 )—, —C(—O—R 26 )alkyl-, —C(—NHR 25 )alkyl-, —C(—NH 2 )alkyl-, —C(—NR 25 2 )alkyl-, —C(R 4 R 4 )—, -alkyl(R 27 )-alkyl(R 28 )—, —C(R 27 R 28 )—, —P(O)(OR 26 )O—, —P(O)(OR 26 )—, —NHC(O)NH—, —N(R 25 )C(O)N(R 25 )—, —N(H)C(O)N(R 25 )—, polyethylene glycol, poly(lactic-co-glycolic acid), alkenyl, haloalkyl, alkoxy, alkyne, aryl, heterocycle, aliphatic, heteroaryl, polypropylene glycol, lactic acid, glycolic acid, and carbocycle;

each of which R 20 , R 21 , R 22 , R 23 , and R 24 is optionally substituted with one or more substituents selected from R 101 ;

R 101 is independently selected at each occurrence from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, hydroxyl, aryl, heteroaryl, heterocycle, arylalkyl, heteroarylalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, CN, —COOalkyl, COOH, NO 2 , F, Cl, Br, I, CF 3 , NH 2 , NHalkyl, N(alkyl) 2 , and aliphatic;

R 25 is selected at each instance from the group consisting of alkyl, —C(O)H, —C(O)OH, —C(O)alkyl, —C(O)Oalkyl, alkenyl, and alkynyl;

R 26 is hydrogen, alkyl, silane, arylalkyl, heteroarylalkyl, alkenyl, or alkynyl;

R 27 and R 28 are independently selected from the group consisting of hydrogen, alkyl, and amine, or together with the carbon atom to which they are attached, form C(O), C(S), C═CH 2 , a C 3 -C 6 spirocarbocycle, or a 4-, 5-, or 6-membered spiroheterocycle comprising 1 or 2 heteroatoms selected from N and O, or form a 1 or 2 carbon bridged ring;

Targeting Ligand binds to a Targeted Protein, wherein the Targeted Protein is an androgen receptor;

the Targeting Ligand is selected from

heteroaryl is independently selected at each instance from a stable aryl ring system containing one or more heteroatoms selected from N, O, and S;

heterocycle is independently selected at each instance from a stable monocyclic 3-8 membered rings and a stable bicyclic 5-16 membered rings containing one or more heteroatoms selected from N, O, and S;

aliphatic is independently selected at each instance from alkyl, alkenyl, and alkynyl;

wherein the variables are selected such that the resulting compound is stable.

2. The compound of claim 1 , wherein n is 0.

3. The compound of claim 1 , wherein the compound is:

4. The compound of claim 1 , wherein the Linker is:

5. The compound of claim 4 , wherein the Linker is:

6. The compound of claim 5 , wherein X 2 is bond.

7. The compound of claim 6 , wherein R 21 is heterocycle.

8. The compound of claim 4 , wherein: R 20 , R 21 , R 22 , R 23 , and R 24 are independently selected from the group consisting of bond, alkyl, —C(O)— —(O)O—, —OC(O)—, —C(O)alkyl, —C(O)Oalkyl, —C(O)NH—, —NHC(O)—, —N(alkyl)C(O)—, —C(O)N(alkyl)-, —O—, —NH—, —N(alkyl)-, —CH(—O—R 26 )—, —CH(—NHR 25 )—, —CH(—NH 2 )—, —CH(—NR 25 2 )—, —C(—O—R 26 )alkyl-, aryl, heterocycle, and aliphatic.

9. The compound of claim 4 , wherein R 20 , R 21 , R 22 , R 23 , and R 24 are not substituted.

10. The compound of claim 1 , wherein the Linker is selected from:

11. The compound of claim 1 , wherein the Linker is selected from:

12. The compound of claim 1 , wherein R 5 is selected at each instance from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, and haloalkyl.

13. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

14. The compound of claim 1 , wherein the Targeting Ligand is:

15. The compound of claim 1 , wherein the Targeting Ligand is:

16. The compound of claim 1 , wherein the Targeting Ligand is:

17. The compound of claim 1 , wherein each heteroaryl group is independently selected from the group consisting of pyrrolyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, and thiadiazolyl.

18. The compound of claim 1 , wherein each heterocycle group is independently selected from the group consisting of pyrrolidinyl, piperidinyl, pyrrolinyl, piperazinyl, and morpholinyl.

19. The compound of claim 1 , wherein n is 1.

20. The compound of claim 1 , wherein n is 2.

21. The compound of claim 16 , wherein n is 0.

22. The compound of claim 16 , wherein n is 1.

23. The compound of claim 16 , wherein n is 2.